Innovest Global has closed the acquisition of Authority National Supply (ANS) and has signed an LOI to acquire Midwest Curtainwalls.
Innovest Global, Inc. $IVST #stock is a diversified Public Holding company that is already a ten-bagger this year with much more on the way based on fundamentals AND technicals!
IVST #stock has closed the acquisition of Authority National Supply (ANS). ANS was our sixth transaction to date, and has generated $22.8 million in sales through the first three quarters of 2018. IVST now has approximately 55 employees and $34 million in annual run-rate revenue.
Innovest Global Signed an LOI to Acquire Midwest Curtainwalls, a $12 Million Revenue and Profitable Business. Midwest is a company that will add to our Construction and Building Materials efforts. They generate $10-$12 million in annual revenue from specialty commercial construction contracts, with projections of $2.4 million in profit from current contract.
Innovest Global, Inc. (OTC Markets: IVST #stock) is in the Conglomerates industry, a diversified holding company with operations in commercial and industrial products and services, energy, biotechnology, and health services. Our primary growth strategy is to acquire niche, high-growth businesses that are capable of generating significant annual revenue. Planned subsidiaries operate across telehealth, biotech, building materials, commercial energy, business-to-business distribution, national call center and auto sales.
Based out of Cleveland, Ohio, IVST #stock is easily one of the better fundamental companies trading on the OTC marketplace. Innovest Global, Inc. is already up 10-fold in 2018, after starting off 2018 around $0.02 before shooting to an all-time high of $0.50 in March 2018. IVST continues to hold onto the nice gains thus far holding strong in the .25-.30 range ready for the next leg back into the .50 range it tested earlier this year. Based upon the company’s strong fundamental AND technical picture, Innovest Global, Inc. could easily retake its all-time high by the end of 2018.
Whata stock structureIVST #stock has investors! The company has an amazing unchanged free-trading float of 11,796,710 common shares with no convertible debts, no warrants or options outstanding, and employs 45.
IVST #Stock owns 20% of StemVax Therapeutics which is the first company in its Biotech Division. StemVax Therapeutics is a Translational Biotechnology Company that develops novel therapies for brain tumor patients. Lead by world-renowned neuroscientist, Dr. Dwain Morris-Irvin, the Biotech & Health Sciences Division is currently focused on commercializing StemVax’s cancer vaccination therapy technology. The cancer vaccination therapy technology was just recently awarded a U.S. patent!.IVST #stock has the vision and model of Berkshire-Hathaway holding company; we look forward to its evolution! www.otcivst.com